Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.
The confirmation that most cancers express one or more molecular changes, which may act as tumour-associated antigens (TAA), combined with the knowledge that T lymphocytes recognize even single amino acid differences in MHC presented peptides has stimulated renewed clinical interest in immunotherapeutic strategies. Dendritic cells (DC) are now recognized as specialist antigen-presenting cells, which initiate, direct and regulate immune responses. Recent data suggest that DC are not recruited into, or activated by, cancers and that other abnormalities in DC function are associated with malignancy, including multiple myeloma. This provides a rationale for designing immunotherapeutic strategies, which exploit DC as nature's adjuvant either in vivo or in vitro. Low-grade lymphoma and multiple myeloma are slowly progressive malignancies, which generally express a unique immunoglobulin idiotype as a potential TAA. Data from animal models and clinical studies suggest that DC-based immunotherapy strategies, applied when the patient has minimal residual disease, may improve the long-term prognosis in these diseases.
Hart
D N
DN
Mater Medical Research Institute and Cancer Services, Mater Adult Hospital, South Brisbane, Queensland, Australia.dhart@mater.org.au
Hill
G R
GR
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D002452:Cell Count; D002454:Cell Differentiation; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000502:physiology / Q000637:transplantation*; D006801:Humans; D007116:Immunization, Passive; D007130:Immunoglobulin Idiotypes / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy*; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy
D000951:Antigens, Neoplasm; D007130:Immunoglobulin Idiotypes